Ironwood Pharmaceuticals (IRWD) Convertible Debt (2015 - 2025)

Ironwood Pharmaceuticals has disclosed Convertible Debt across 11 years of filings, most recently posting $199.2 million for Q1 2025.

• In Q1 2025, Convertible Debt changed 0.34% year-over-year to $199.2 million; the TTM figure through Mar 2025 stood at $199.2 million (changed 0.34% YoY), while the FY2024 annual figure was $199.0 million, changed 0.34% from the prior year.
• Convertible Debt came in at $199.2 million for Q1 2025 at Ironwood Pharmaceuticals, roughly flat from $199.0 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $436.1 million in Q1 2021 to a low of $198.0 million in Q2 2023.
• Average Convertible Debt over 5 years is $294.3 million, with a median of $329.2 million recorded in 2021.
• Year-over-year, Convertible Debt gained 20.14% in 2022 and plunged 49.96% in 2024.
• Over 5 years, Convertible Debt stood at $337.3 million in 2021, then increased by 17.47% to $396.3 million in 2022, then slumped by 49.95% to $198.3 million in 2023, then gained by 0.34% to $199.0 million in 2024, then advanced by 0.09% to $199.2 million in 2025.
• Per Business Quant data, the three most recent Convertible Debt figures were $199.2 million in Q1 2025, $199.0 million in Q4 2024, and $198.8 million in Q3 2024.